^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    3ms
    A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (clinicaltrials.gov)
    P=N/A, N=35, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    3ms
    A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=404, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    paclitaxel • topotecan • trastuzumab brengitecan (BL-M07D1)
    3ms
    IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer (clinicaltrials.gov)
    P1, N=19, Not yet recruiting, Shanghai Gynecologic Oncology Group
    New P1 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    Trodelvy (sacituzumab govitecan-hziy)
    3ms
    Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date • Platinum sensitive
    |
    carboplatin • gemcitabine • berzosertib (M6620)
    3ms
    Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=22, Completed, University of Washington | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin
    3ms
    Accelerated Bilateral Cataract Progression during Olaparib plus Bevacizumab Maintenance Therapy for High-Grade Serous Fallopian Tube Carcinoma: A Case Report. (PubMed, Case Rep Oncol)
    After neoadjuvant chemotherapy with paclitaxel, carboplatin, and bevacizumab, followed by interval debulking surgery and postoperative chemotherapy, she achieved a complete response and began maintenance therapy with bevacizumab plus olaparib. This case highlights a previously unreported ocular adverse event associated with combined PARP inhibitor and anti-VEGF maintenance therapy. Clinicians should maintain vigilance for visual symptoms and consider periodic ophthalmologic monitoring in patients receiving prolonged olaparib-based therapy.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • paclitaxel
    3ms
    OVACT: Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=50, Recruiting, Epitopea Ltd
    New P1 trial
    3ms
    NEO: A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=71, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • BARD1 (BRCA1 Associated RING Domain 1) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D) • FANCM (FA Complementation Group M)
    |
    BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    |
    Lynparza (olaparib)
    3ms
    Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P1, N=31, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Zejula (niraparib) • Aliqopa (copanlisib)
    3ms
    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Alexander B Olawaiye, MD | Trial completion date: Mar 2033 --> Dec 2034 | Trial primary completion date: Dec 2031 --> Nov 2033
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Talzenna (talazoparib) • ZEN-3694
    3ms
    Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=48, Recruiting, Ronald Buckanovich | Trial completion date: Mar 2033 --> Sep 2032 | Trial primary completion date: Mar 2031 --> Aug 2031
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • Erivedge (vismodegib)
    3ms
    FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (clinicaltrials.gov)
    P3, N=1630, Recruiting, Eli Lilly and Company | N=1080 --> 1630 | Trial primary completion date: Apr 2028 --> Nov 2028
    Enrollment change • Trial primary completion date • Platinum sensitive • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • sofetabart mipitecan (LY4170156)